XML 30 R43.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Segments of Business and Geographic Areas (Details 1) (USD $) In Millions, unless otherwise specified | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 29, 2013 | Sep. 30, 2012 | Sep. 29, 2013 | Sep. 30, 2012
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |
Total Segment Operating Income | $ 3,872 |  | $ 3,825 |  | $ 13,374 |  | $ 11,613 |
Percentage Change in Operating Income Loss Excluding Expenses Not Allocated to Segments | 1.20% |  |  |  | 15.20% |  |  |
Percentage Change in Operating Income Loss | 2.00% |  |  |  | 19.20% |  |  |
Less: Expense not allocated to segments | 205 | [1] | 230 | [1] | 653 | [1] | 938 | [1]
Earnings before provision for taxes on income | 3,667 |  | 3,595 |  | 12,721 |  | 10,675 |
Consumer [Member] |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |
Total Segment Operating Income | 467 | [2] | 510 | [2] | 1,525 | [2] | 1,239 | [2]
Percentage Change in Operating Income Loss | (8.40%) |  |  |  | 23.10% |  |  |
Pharmaceutical [Member] |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |
Total Segment Operating Income | 2,449 | [3] | 1,388 | [3] | 7,858 | [3] | 4,494 | [3]
Percentage Change in Operating Income Loss | 76.40% |  |  |  | 74.90% |  |  |
Medical Devices and Diagnostics [Member] |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |
Total Segment Operating Income | $ 956 | [4] | $ 1,927 | [4] | $ 3,991 | [4] | $ 5,880 | [4]
Percentage Change in Operating Income Loss | (50.40%) |  |  |  | (32.10%) |  |  |
[1] | Amounts not allocated to segments include interest income/(expense), noncontrolling interests and general corporate income/expense. The fiscal nine months of 2013 includes litigation expense of $6 million. The fiscal nine months of 2012 includes currency losses related to the Synthes acquisition of $234 million and litigation expense of $11 million.
[2] | Includes a gain on the sale of intangible and other assets of $55 million recorded in the fiscal nine months of 2013. Includes intangible asset write-downs of $294 million recorded in the fiscal nine months of 2012.
[3] | Includes in-process research and development charges of $178 million and litigation expense of $28 million recorded in the fiscal third quarter of 2013. Includes litigation expense of $206 million, in-process research and development charges of $178 million and a net gain of $400 million on equity investment transactions, primarily the sale of Elan American Depositary Shares recorded in the fiscal nine months of 2013. Includes in-process research and development charges of $679 million recorded in the fiscal third quarter of 2012. Includes in-process research and development charges of $1,108 million, litigation expense of $658 million and intangible asset write-downs of $499 million recorded in the fiscal nine months of 2012.
[4] | Includes litigation expense of $844 million, Synthes integration/transaction costs of $122 million and $35 million for the ASR™ Hip program recorded in the fiscal third quarter of 2013. Includes litigation expense of $1,564 million, Synthes integration/transaction costs of $502 million, in-process research and development charges of $64 million and $117 million for the ASR™ Hip program in the fiscal nine months of 2013. Includes Synthes integration/transaction costs of $165 million, litigation expense of $89 million and $27 million for the ASR™ Hip program recorded in the fiscal third quarter of 2012. Includes Synthes integration/transaction costs of $388 million, intangible asset write-downs of $146 million, litigation expense of $89 million and $27 million for the ASR™ Hip program recorded in the fiscal nine months of 2012.

X
- Definition Expense not allocated to segments. + References No definition available. + Details
Name: | jnj_ExpenseNotAllocatedToSegments
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage change in operating income loss. + References No definition available. + Details
Name: | jnj_PercentageChangeInOperatingIncomeLoss
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage change in operating income loss excluding expenses not allocated to segments. + References No definition available. + Details
Name: | jnj_PercentageChangeInOperatingIncomeLossExcludingExpensesNotAllocatedToSegments
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration